Semaglutide 30mg – 10 vials

Semaglutide is a synthetic analogue of glucagon-like peptide-1 (GLP-1), a naturally occurring incretin hormone secreted in response to nutrient ingestion. As a GLP-1 receptor agonist, semaglutide exerts its effects by binding to and activating GLP-1 receptors distributed throughout the pancreas, central nervous system, gastrointestinal tract, and cardiovascular tissues. In research settings, it has been extensively investigated for its ability to potentiate glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and modulate hypothalamic appetite-regulating pathways.

This 30mg lyophilised powder format is suitable for in vitro and preclinical in vivo research into type 2 diabetes models, obesity and energy homeostasis, cardiovascular risk factor modulation, and neuroprotective mechanisms. Semaglutide’s extended half-life relative to native GLP-1 is attributed to its albumin-binding fatty acid side chain and modifications at positions 8 and 34 of the peptide backbone, making it a valuable tool compound for sustained-exposure pharmacodynamic studies.

Store at -20°C, protected from light and moisture. Reconstitute in sterile bacteriostatic water or relevant buffer prior to use.

For research purposes only. Not for human use.